The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy
(SCIT) with House Dust Mite (HDM) extract in patients with rhinoconjunctivitis with or
without associated mild asthma and sensitized to HDM. In addition,surrogate efficacy
parameters will be evaluated: immunoglobulin level changes and skin reactivity.
It will be recruited 50 patients susceptible to receive SCIT with HDM extract along 5
participating spanish sites.
Primary endpoint of the study is to assess the safety and tolerability of subcutaneous
immunotherapy in depot presentation and quick pattern in patients with rhinoconjunctivitis
with or without mild asthma sensitized to house dust mites
Secondary objective is to evaluate the indirect immunotherapy efficacy through the
measurement of immunoglobulin level changes and cutaneous reactivity